New drug therapy for patients with HIV. Nursing implications in the administration of 2',3'-dideoxyinosine (ddI).
2',3'-Dideoxyinosine (ddI) is a dideoxynucleoside currently in Phase I, II, and III trials for antiretroviral therapy. It has been shown to cause objective and subjective improvement in people with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex (ARC). This drug, as with any drug, is not without toxicity. Through thorough patient education and clinical evaluation, incidence of these toxicities may be lessened or avoided.
Shay
L E
LE
Medicine Branch, NCI, NIH, Bethesda, Maryland 20892.
Thomas
R V
RV
Wyvill
K M
KM
Adamo
D O
DO
Jenkins
J F
JF
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000451:nursing; D002986:Clinical Trials as Topic; D016049:Didanosine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D015497:HIV-1; D006801:Humans; D010347:Patient Care Planning; D010353:Patient Education as Topic
D016049:Didanosine